Table of Contents
<< Previous Issue | May 2020 (Vol: 2020, Issue: 5) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Alexion Acquires Portola for US$1.44 B
-
PTC Therapeutics Acquires Censa Pharmaceuticals
- Section: Research & Development
-
Gilead and Second Genome Sign US$1.5 B Microbiome-based Drug Discovery Deal
-
Vertex Signs US$1.6 B Gene Therapy Vector Partnership with Affinia
-
Dyno Therapeutics Launches with US$2 B Deals with Novartis and Sarepta
-
Fate Therapeutics Partners with Janssen for iPSC-derived Immunotherapies